Table 1.
Demographic, clinical and laboratory characteristic data of study patients.
| General Conditions | SLE Patients | Healthy Donors |
|---|---|---|
| Age in years, mean ± SD | 50.4 ± 15.29 | 52.2 ± 17.7 |
| Gender, % (n) women | 93.75 (45) | 90 (18) |
| Years of development, median (IQR) | 9 (3–17) | |
| SLEDAI, mean (range) | 2.89 (0–10) | |
| Laboratory parameters | ||
| C3 (mg/dL, median (IQR)) | 75.1 (63.03–100.8) | |
| Decreased C3 or C4, % (n) | 66.7 (32) | |
| Positive anti-dsDNA, % (n) | 41.7 (20) | |
| Positive ANA, % (n) | 91.7 (44) | |
| Positive anti-Sm, % (n) | 23 (11) | |
| Positive anti-C1q, % (n) | 43 (20) | |
| Positive anti-SSB-La, % (n) | 16 (7) | |
| Positive anti-SSA-Ro, % (n) | 44 (20) | |
| Positive anti-U1-RNP, % (n) | 30 (14) | |
| Positive antiphospholipid antibody, % (n) | 27 (13) | |
| Leukopenia and/or lymphopenia, % (n) | 37.5 (18) | |
| Clinical features, % (n) | ||
| Renal involvement | 41.7 (20) | |
| Hematuria | 27.1 (13) | |
| Albumin/creatinine > 2.5 | 14.6 (7) | |
| Cutaneous involvement | 18.8 (9) | |
| Arthritis | 14.6 (7) | |
| Treatment, % (n) | ||
| None | 6 (3) | |
| Mycophenolate | 17 (8) | |
| Prednisone | 37 (18) | |
| Hydroxychloroquine | 79 (38) | |
| Azathioprine | 8 (4) |